Document Type

Article

Publication Date

5-25-2021

Publication Title

Alzheimer's & Dementia: Translational Research & Clinical Interventions

Volume

7

Issue

1

First page number:

1

Last page number:

24

Abstract

Introduction The number of individuals worldwide with Alzheimer's disease (AD) is growing at a rapid rate. New treatments are urgently needed. We review the current pipeline of drugs in clinical trials for the treatment of AD. Methods We interrogated ClinicalTrials.gov, the federal registry of clinical trials to identify drugs in trials. Results There are 126 agents in 152 trials assessing new therapies for AD: 28 treatments in Phase 3 trials, 74 in Phase 2, and 24 in Phase 1. The majority of drugs in trials (82.5%) target the underlying biology of AD with the intent of disease modification; 10.3% are putative cognitive enhancing agents; and 7.1% are drugs being developed to reduce neuropsychiatric symptoms. Discussion This pipeline analysis shows that target biological processes are more diversified, biomarkers are more regularly used, and repurposed agents are being explored to determine their utility for the treatment of AD.

Keywords

Alzheimer's disease; amyloid biomarkers; clinical trials; Common Alzheimer's Disease Research Ontology (CADRO); drug development; inflammation; National Institutes of Health; pharmaceutical companies; repurposed drugs

Disciplines

Nervous System Diseases | Neuroscience and Neurobiology | Pharmacology

File Format

PDF

File Size

2300 KB

Language

English

Creative Commons License

Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Download

UNLV article access

Search your library

Share

COinS